Pharmacy and Therapeutics (P&T) Committee
Related Links
The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.
Change Healthcare provides clinical and financial analysis support to the P&T Committee.
P&T Committee Meeting Information
Upcoming Meetings
Dates:
Tuesday, September 13, 2022, 12:00pm-4:00pm EDT and Wednesday, September 14, 2022, 9:00am-4:00pm EDT
Location:
The September P&T Committee meetings will be held virtually.
Register for the Webinars:
Register for DHS Pharmacy & Therapeutics Committee on September 14, 2022, 9:00 AM EDT at:
https://attendee.gotowebinar.com/register/9038263078885454091
Register for DHS Pharmacy & Therapeutics Committee on September 13, 2022, 12:00 PM EDT at:
https://attendee.gotowebinar.com/register/2378875192190072079
Public Testimony:
All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings.
Regisration for testimony must be received by Tuesday, August 30, 2022. To register, please go to: https://papdl.com/.
Written testimony will be accepted and must be submitted by Tuesday, August, 30, 2022. The written testimony will be distributed to all P&T Committee members prior to the meetings. Testimony should be emailed to RA-PharmForms@pa.gov.
Drug Classes for Review:
| Acne Agents, Oral | Cephalosporins | Migraine Acute Treatment Agents |
| Acne Agents, Topical | Colony Stimulating Factors | Migraine Prevention Agents |
| Alcohol Use Disorder | Contraceptives, Oral | Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP |
| Alzheimer's Agents | Contraceptives, Other | Multiple Sclerosis Agents |
| Analgesics, Non-Opioid Barbiturate Combinations | COPD Agents | Neuropathic Pain Agents |
| Analgesics, Opioid Long-Acting | Cytokine and CAM Antagonists | NSAIDs |
| Analgeiscs, Opioid Short-Acting | Enzyme Replacements, Gaucher Disease | Oncology Agents, Breast Cancer |
| Androgenic Agents | Epinephrine, Self-Injected | Oncology Agents, Oral |
| Angiotensin Modulator Combinations | Erythropoiesis Stimulating Agents | Ophthalmics, Allergic Conjunctivitis |
| Angiotensin Modulators | Estrogens | Ophthalmics, Antibiotics |
| Antianginal Agents | Fluoroquinolones, Oral | Ophthalmics, Antibiotics-Steroid Combinations |
| Antibiotics, GI and Related Agents | GI Motility, Chronic Agents | Ophthalmics, Anti-Inflammatories |
| Antibiotics, Inhaled | Glucocorticoids, Inhaled | Ophthalmics, Dry Eye |
| Antibiotics, Topical | Glucocorticoids, Oral | Ophthalmics, Glaucoma |
| Anticoagulants | Growth Hormones | Opioid Dependence Treatments |
| Anticonvulsants | H. Pylori Treatments | Opioid Overdose Agents |
| Antidepressants, Other | Hematopoietic Mixtures | Otic Antibiotic Preparations |
| Antidepressants, SSRIs | Hepatitis B Agents | Pancreatic Enzymes |
| Antiemetics/Antivertigo Agents | Hepatitis C Agents | Penicillins |
| Antifungals, Orals | Hereditary Angioedema (HAE) Agents | Phosphate Binders |
| Antifungals, Topical | Histamine 2 Receptor Blockers | Pituitary Suppressive Agents, LHRH |
| Antihemophilia Agents | HIV/AIDS Antiretrovirals | Platelet Aggregation Inhibitors |
| Antihistamines, Minimally Sedating | Hypoglycemia Treatments | Potassium Removing Agents |
| Antihypertensives, Sympatholytic | Hypoglycemics, Alpha-Glucosidase Inhibitors | Prenatal Vitamins |
| Antihyperuricemics | Hypoglycemics, Incretin Mimetics/Enhancers | Progestational Agents |
| Antimalarials | Hypoglycemics, Insulin and Related Agents | Proton Pump Inhibitors (PPIs) |
| Anti-Obesity Agents | Hypoglycemics, Meglitinides | Pulmonary Fibrosis Agents |
| Antiparasitics, Topical | Hypoglycemics, Metformins | Pulmonary Hypertension Agents, Oral and Inhaled |
| Antiparkinson's Agents | Hypoglycemics, SGLT2 Inhibitors | Sedative Hypnotics |
| Antipsoriatics, Oral | Hypoglycemics, Sulfonylureas | Sickle Cell Anemia Agents |
| Antipsoriatics, Topical | Hypoglycemics, TZDs | Skeletal Muscle Relaxants |
| Antipsychotics | Immunomodulators, Atopic Dermatitis | Smoking Cessation Products |
| Antivirals, CMV | Immunomodulators, Topical | Steroids, Topical |
| Antivirals, Herpes | Immunosuppressives, Oral | Stimulants and Related Agents |
| Antivirals, Influenza | Intra-Articular Hyaluronates | Tetracyclines |
| Anxiolytics | Intranasal Rhinitis Agents | Thalidomide and Derivatives |
| Benign Prostatic Hyperplasia (BPH) Treatments | Iron Chelating Agents | Thrombopoietics |
| Beta Blockers | Iron, Parenteral | Thyroid Hormones |
| Bile Salts | Leukotriene Modifiers | Ulcerative Colitis Agents |
| Bladder Relaxant Preparations | Lipotropics, Other | Urea Cycle Disorder Agents |
| Blood Glucose Meters and Test Strips | Lipotropics, Statins | Urinary Anti-Infectives |
| Bone Density Regulators | Local Anesthetics, Topical | Vaginal Anti-Infectives |
| Botulinum Toxins | Macrolides | Vitamin D Analogs |
| Bronchodilators, Beta Agonists | Macular Degenerations Agents | VMAT2 Inhibitors |
| Calcium Channel Blockers | Methotrexate |
|
Past Pharmacy and Therapeutics Committee Meetings
Review the Pharmacy and Therapeutics Committee By-Laws
Committee Information
Composition and responsibilities of the committee:
- Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
- Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
- Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
- Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.
|
Name |
Specialty |
Independent* |
Department** |
MCO |
| Ivonne Acrich, MD | Ad Hoc Child/Adolescent Psychiatrist
| | X | |
| Dale Adair, MD, FAPA | Office of Mental Health & Substance Abuse Services Medical Director | | X | |
| Christopher Antypas, PharmD | Community Pharmacist | X | | |
| Lawrence Appel, MD, SFHM | Medical Director, Office of Long Term Living
| | X
| |
| Cheston Berlin, Jr., MD | Pediatrician | X
| | |
| Tony Byler, MD | PerformCare Psychiatrist | | | X |
Terri Cathers, PharmD,
Chair (tie-breaker vote only) | OMAP Pharmacy Director
|
| X | |
| Sharon Connor, PharmD | Academic Pharmacist | X | | |
Molly DiMatteo, DO
| Family Practitioner
| X
| | |
| Oluwatoyin Fadeyibi, PharmD, MPH | Community Behavioral Health Pharmacist | | | X |
| Andrea Fox, MD | Internist | X | | |
| Donald Gerhart, RPh | Community Pharmacist | X | | |
| James Hancovsky, RPh, MBA | United Health Care Pharmacy Director | | | X |
| Rosemary Keffer, MD | Ad Hoc Adult Psychiatrist | X | | |
David Kelley, MD
| OMAP Chief Medical Officer, Office of Medical Assistance Programs | | X | |
| Peter Kreckel, RPh | Community Pharmacist | X | | |
| Renee Licwinko, RPh | Gateway Health Plan Pharmacist | | | X |
| Andrew Maiorini, PharmD | Keystone/AmeriHealth Perform Rx Clinical Pharmacist | | | X |
| Meghan McNelly, PharmD | PA Health & Wellness Pharmacist | | | X |
| Michele Musheno, RPh, MS | Academic/Hospital Pharmacist | X | | |
| Geoffrey Neimark, MD | Community Care Behavioral Health Psychiatrist | | | X |
| Natalie Nkurunziza, PharmD | Aetna Better Health Pharmacist | | | X |
| Louis Parrott Jr., MD, PhD | Magellan Healthcare Psychiatrist | | | X |
| Ian Paul, MD | Pediatrician | X | | |
| Adam Raphael Rom, MD | Family Practitioner | X | | |
| Amy Saracino, MD | Ad Hoc Adult Psychiatrist | | X | |
| Kevin Szczecina, RPh | Geisinger Health Plan Pharmacist | | | X |
| Mahmood Usman, MD | Beacon Health Options Psychiatrist | | | X |
Fallan Vaisberg, PharmD, RPh
| Health Partners Plans Formulary Pharmacist
|
|
| X
|
| Andreas Wali, MD | Cardiologist | X | | |
| Lloyd Wertz | Consumer/Family Advocate | X | | |
| Lauren Zandier, PharmD | UPMC For You Pharmacist | | | X |
| Vacant | Consumer Representative | X | | |
* - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis
Effective August 8, 2022 / Last modified August 8, 2022